콘텐츠로 건너뛰기
Merck

주요 문서

모든 문서 보기

D9766

Dipyridamole

≥98% (HPLC), powder, phosphodiesterase V inhibitor

동의어(들):

NSC 515776, NSC 619103

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C24H40N8O4
CAS 번호:
58-32-2
Molecular Weight:
504.63
NACRES:
NA.77
PubChem Substance ID:
24277705
UNSPSC Code:
41106305
EC Number:
200-374-7
MDL number:
MFCD00010555
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
200
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의

제품 이름

Dipyridamole, ≥98% (HPLC)

Quality Level

200

assay

≥98% (HPLC)

form

powder

color

yellow

mp

165-166 °C (lit.)

solubility

DMSO: soluble, ethanol: soluble

originator

Boehringer Ingelheim

storage temp.

room temp

SMILES string

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

InChI key

IZEKFCXSFNUWAM-UHFFFAOYSA-N

Gene Information

human ... CYP1A2(1544), PDE10A(10846), PDE1A(5136), PDE1B(5153), PDE1C(5137), PDE2A(5138), PDE3A(5139), PDE3B(5140), PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144), PDE5A(8654), PDE6A(5145), PDE6B(5158), PDE6C(5146), PDE6D(5147), PDE6G(5148), PDE6H(5149), PDE7A(5150), PDE7B(27115), PDE8A(5151), PDE8B(8622), PDE9A(5152), SLC29A1(2030)
mouse ... Slc29a1(63959)

General description

Dipyridamole prevents cellular uptake of adenosine. It functions as an equilibrative nucleoside transporter 1 (ENT1) inhibitor.

Application

Dipyridamole has been used:
  • to perform in vitro growth inhibition assay(40)
  • to determine its ability to prevent uterine myometrial contractions(41)
  • to determine its effects on nicotinamide adenine dinucleotide (NAD+)-induced increase in intracellular adenosine triphosphate (ATP) levels(42)
  • to prevent nicotinamide riboside (NR)-induced axonal protection(43)

Biochem/physiol Actions

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under

저장 등급

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
128K1287
098K1188
018K1264
077K1235
125H0406

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

문서

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

고리형 뉴클레오타이드를 위한 생체 활성 저분자

고리형 AMP(cAMP), 고리형 GMP(cGMP), 고리형 ADP-리보스를 포함하여 고리형 뉴클레오타이드는 GPCR 활성화에 의해 개시된 세포내 이벤트의 2차 전달자로서 광범위하게 연구되었습니다. cAMP는 주로 cAMP 의존성 단백질 인산화효소(PKA)의 활성화를 통해 모든 진핵생물 세포에서 세포 기능을 변형시키지만 cAMP 개폐 이온 채널 및 cAMP에 의해 직접 활성화되는 구아닌 뉴클레오타이드 교환 인자를 통해서도 변형시킵니다.

Extracellular Degradation into Adenosine and the Activities of Adenosine Kinase and AMPK Mediate Extracellular NAD+-produced increases in the Adenylate Pool of BV2 Microglia under Basal Conditions
Zhang J, et al.
Frontiers in Cellular Neuroscience, 12 (2018)
J A Thorn et al.
General pharmacology, 27(4), 613-620 (1996-06-01)
1. In mammals, nucleoside transport is an important determinant of the pharmacokinetics, plasma and tissue concentration, disposition and in vivo biological activity of adenosine as well as nucleoside analogues used in antiviral and anticancer therapies. 2. Two broad types of
Nyoli Valentine et al.
The Cochrane database of systematic reviews, 11, CD005449-CD005449 (2012-11-16)
Cardiovascular disease (CVD) is the most prevalent complication of type 2 diabetes with an estimated 65% of people with type 2 diabetes dying from a cause related to atherosclerosis. Adenosine-diphosphate (ADP) receptor antagonists like clopidogrel, ticlopidine, prasugrel and ticagrelor impair
모든 관련된 서류 보기

국제 무역 품목 번호

SKUGTIN
D9766-1G04061826682494
D9766-5G04061833591109
D9766-10G04061832897882
D9766-25G04061832897899